INmune Bio, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own35.05% Shs Outstand17.95M Perf Week-13.17%
Market Cap118.98M Forward P/E- EPS next Y-2.10 Insider Trans0.04% Shs Float11.66M Perf Month-38.31%
Income-27.30M PEG- EPS next Q-0.02 Inst Own10.70% Short Float / Ratio9.22% / 19.38 Perf Quarter-17.44%
Sales0.40M P/S297.44 EPS this Y19.00% Inst Trans-4.56% Short Interest1.07M Perf Half Y-20.92%
Book/sh3.35 P/B1.85 EPS next Y-26.50% ROA-31.40% Target Price18.00 Perf Year-22.79%
Cash/sh2.72 P/C2.28 EPS next 5Y- ROE-40.50% 52W Range4.63 - 10.75 Perf YTD-2.21%
Dividend- P/FCF- EPS past 5Y- ROI-34.70% 52W High-42.33% Beta2.05
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low33.94% ATR0.62
Employees10 Current Ratio5.90 Sales Q/Q-50.00% Oper. Margin- RSI (14)28.33 Volatility8.82% 7.63%
OptionableYes Debt/Eq0.24 EPS Q/Q40.00% Profit Margin- Rel Volume1.66 Prev Close6.58
ShortableYes LT Debt/Eq0.16 EarningsMar 02 AMC Payout- Avg Volume55.46K Price6.20
Recom1.50 SMA20-25.48% SMA50-26.22% SMA200-22.48% Volume92,036 Change-5.78%
May-24-22Downgrade B. Riley Securities Buy → Neutral $14 → $7
Jul-07-21Reiterated Maxim Group Buy $32 → $42
Apr-21-21Initiated B. Riley Securities Buy $29
Jan-22-21Reiterated Maxim Group Buy $16 → $32
Sep-01-20Initiated BTIG Research Buy $23
Jul-15-20Reiterated H.C. Wainwright Buy $7 → $20
Mar-20-23 06:46AM
Mar-06-23 09:48AM
Mar-03-23 09:53AM
Mar-02-23 04:05PM
Feb-21-23 09:00AM
08:45AM Loading…
Feb-08-23 08:45AM
Jan-25-23 07:45AM
Dec-22-22 08:00AM
Dec-21-22 09:55AM
Dec-08-22 08:00AM
Dec-06-22 04:00PM
Nov-29-22 08:00AM
Nov-20-22 07:34AM
Nov-14-22 09:00AM
Nov-02-22 04:00PM
08:10AM Loading…
Oct-26-22 08:10AM
Oct-19-22 11:48AM
Oct-10-22 11:46AM
Sep-07-22 09:00AM
Aug-04-22 05:00AM
Aug-03-22 04:10PM
Jul-27-22 08:00AM
Jul-25-22 08:00AM
Jul-17-22 08:19AM
Jun-22-22 08:00AM
Jun-16-22 08:00AM
Jun-09-22 07:35AM
Jun-07-22 09:55AM
06:22AM Loading…
Jun-02-22 06:22AM
May-25-22 12:07PM
May-24-22 08:59AM
May-23-22 04:00PM
May-18-22 09:00AM
May-10-22 08:00AM
May-06-22 01:30PM
May-05-22 04:00PM
May-03-22 11:44AM
Apr-28-22 07:00AM
Apr-25-22 04:00PM
Apr-14-22 03:38PM
Apr-13-22 04:00PM
Apr-11-22 08:00AM
Apr-04-22 09:00AM
Mar-30-22 08:00AM
Mar-25-22 09:00AM
Mar-15-22 08:00AM
Mar-14-22 04:30PM
Mar-04-22 04:30AM
Mar-03-22 04:00PM
Feb-23-22 09:00AM
Feb-08-22 09:00AM
Feb-07-22 07:14AM
Jan-25-22 09:00AM
Jan-04-22 09:00AM
Dec-09-21 09:01AM
Dec-01-21 09:00AM
Nov-15-21 08:00AM
Nov-08-21 06:34AM
Nov-04-21 03:01AM
Nov-03-21 04:15PM
Oct-27-21 09:00AM
Oct-25-21 09:00AM
Sep-27-21 04:00PM
Sep-23-21 12:12PM
Sep-22-21 02:44PM
Sep-20-21 04:00PM
Sep-08-21 12:02PM
Sep-02-21 04:13PM
Sep-01-21 04:45PM
Aug-26-21 12:56PM
Aug-25-21 04:00PM
Aug-10-21 09:00AM
Aug-05-21 08:15AM
Aug-04-21 04:20PM
Jul-28-21 04:05PM
Jul-26-21 08:30AM
Jul-25-21 05:36AM
Jul-23-21 04:20PM
Jul-22-21 11:53AM
Jul-19-21 08:30AM
Jul-14-21 11:45AM
Jul-12-21 05:25PM
Jul-07-21 09:47AM
Jun-14-21 04:01PM
Jun-13-21 10:59PM
Jun-02-21 09:00AM
May-24-21 09:00AM
May-06-21 04:01AM
May-05-21 04:15PM
Apr-28-21 09:00AM
Apr-26-21 09:00AM
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moss David JCFO, Treasurer & SecretaryMar 17Buy6.422,50016,0621,250,151Mar 20 08:02 AM
Moss David JCFO, Treasurer & SecretaryMay 27Buy6.793,00020,3701,247,651May 31 06:08 AM
Moss David JCFO, Treasurer & SecretaryMay 26Buy6.277,70048,2791,244,651May 31 06:08 AM
Tesi Raymond JosephPresident and CEOMay 26Buy6.416,30040,3831,520,698May 31 06:10 AM